Clinical Trial Update: Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pramipexole or risperidone for refractory obsessive-compulsive disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Pramipexole (pramipexole)
• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Clinical Academic Center (2CA-Braga) | Conditions: Obsessive-Compulsive Disorder | Phase 2 | Status: WITHDRAWN